Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis

Tabitha Galindo; Jose Reyna; Andy Weyer

doi:10.3390/ph11040105

Evidence for Transient Receptor Potential (TRP) Channel Contribution to Arthritis Pain and Pathogenesis

Pharmaceuticals (Basel). 2018 Oct 15;11(4):105. doi: 10.3390/ph11040105.

Authors

Tabitha Galindo¹, Jose Reyna², Andy Weyer³

Affiliations

¹ School of Physical Therapy and Athletic Training, Pacific University, Hillsboro, OR 97116, USA. tdgalindo@pacificu.edu.
² School of Physical Therapy and Athletic Training, Pacific University, Hillsboro, OR 97116, USA. reyn1741@pacificu.edu.
³ Biological Sciences Department, City College of San Francisco, San Francisco, CA 94112, USA. aweyer@ccsf.edu.

Abstract

Based on clinical and preclinical evidence, Transient Receptor Potential (TRP) channels have emerged as potential drug targets for the treatment of osteoarthritis, rheumatoid arthritis, and gout. This review summarizes the relevant data supporting a role for various TRP channels in arthritis pain and pathogenesis, as well as the current state of pharmacological efforts to ameliorate arthritis symptoms in patient populations.

Keywords: TRP; TRPA1; TRPV1; arthritis; gout; osteoarthritis; rheumatoid arthritis; transient receptor potential.

Publication types

Review